# Anthropometric Indices and Markers of Atherothrombotic Risk in Subjects with Primary Hyperparathyroidism

**Authors:** Anda Mihaela Naciu, Eleonora Sargentini, Marco Bravi, Annunziata Nusca, Francesco Grigioni, Luigi Bonifazi Meffe, Nicola Napoli, Andrea Palermo, Gaia Tabacco

PMC · DOI: 10.3390/metabo16030166 · 2026-02-28

## TL;DR

This study explores how body measurements relate to heart disease risk in people with primary hyperparathyroidism.

## Contribution

The study evaluates novel and traditional anthropometric indices as potential markers of atherothrombotic risk in PHPT.

## Key findings

- PHPT subjects had higher central adiposity indices (WHtR and CI) compared to controls.
- PHPT patients showed significant impairment in FMD and increased IMT compared to other groups.
- Anthropometric indices were not correlated with atherothrombotic risk markers in PHPT patients.

## Abstract

Background: Both primary hyperparathyroidism (PHPT) and chronic hypoparathyroidism (HypoPT) are associated with the onset and development of cardiovascular diseases (CVDs). In particular, PHPT is accompanied by the presence of elevated atherothrombotic risk, while the importance of traditional and new anthropometric indices to reflect the cardiovascular risk remains uncertain in this condition. This study aims to investigate whether novel and traditional anthropometric indices distinguish PHPT and whether these indices are correlated with atherothrombotic risk. Methods: A total of 40 subjects with HypoPT, 40 with PHPT and 40 age- and sex-matched control subjects were consecutively enrolled for the evaluation of flow-mediated vasodilation (FMD) and carotid intima–media thickness (IMT). A blood sample was collected for evaluation of calcium–phosphate metabolism, PTH, TSH and 25-hydroxy vitamin D. Physical examination was performed to obtain traditional anthropometric parameters and derived indices of adiposity and cardiometabolic risk (waist-to-height ratio (WHtR), waist-to-hip ratio (WHR) and conicity index (CI)). Results: The PHPT group showed higher central adiposity indices (WHtR p = 0.002, and CI p = 0.008). Among patients with parathyroid disorders, PHPT subjects displayed the highest reduction in FMD (p < 0.001) and a marked increase in IMT (p < 0.001). In the Ctrl group, WHtR showed a weak-to-moderate positive association with IMT (r = 0.381, p = 0.018). In the PHPT group, no anthropometric index was significantly correlated with IMT or FMD (all p > 0.05). Conclusions: WHtR and CI provide evidence of increased central fat adiposity in PHPT but do not account for impaired atherothrombotic risk, indicating that anthropometric indices may lack relevance to cardiovascular risk in this condition and emphasizing the importance of a specific assessment profile.

## Linked entities

- **Diseases:** primary hyperparathyroidism (MONDO:0010837)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, FSHMD1A (facioscapulohumeral muscular dystrophy 1A) [NCBI Gene 2489] {aka FMD, FSHD, FSHD1A, FSHMD}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** diabetes (MESH:D003920), atherosclerosis (MESH:D050197), medial calcification (MESH:D050380), diseases of endocrine (MESH:D004700), vascular impairment (MESH:D020141), rheumatological or hematological diseases (MESH:D006402), CV (MESH:D002318), alcoholism (MESH:D000437), Cushing's (MESH:D003480), hypocalcemia (MESH:D006996), Bone and Thyroid Disorders (MESH:D001847), malnutrition (MESH:D044342), obesity (MESH:D009765), thyrotoxicosis (MESH:C566386), vascular damage (MESH:D057772), depression (MESH:D003866), parathyroid adenomas (MESH:D010282), malabsorption diseases (MESH:D008286), bowel diseases (MESH:D015212), injury to (MESH:D014947), thyroid nodules (MESH:D016606), visceral adiposity (MESH:D007418), endothelial dysfunction (MESH:D014652), Parathyroid disorders (MESH:D010279), Reactive hyperemia (MESH:D006940), arrhythmias (MESH:D001145), adiposity (MESH:D018205), inflammation (MESH:D007249), hypercalcemia (MESH:D006934), familial hypocalciuric hypercalcemia (MESH:C537145), eating disorders (MESH:D001068), hypertension (MESH:D006973), chronic (MESH:D002908), HypoPT (MESH:D007011), chronic hepatic disease (MESH:D006521), weight loss (MESH:D015431), malignancies (MESH:D009369), Hyperparathyroidism (MESH:D006961), IMT (MESH:D010033), PHPT (MESH:D049950), thyroid cancer (MESH:D013964), metabolic derangements (MESH:D008659), weight gain (MESH:D015430), autoimmune diseases (MESH:D001327)
- **Chemicals:** lipid (MESH:D008055), alcohol (MESH:D000438), 25-hydroxy vitamin D (MESH:C104450), sodium citrate (MESH:D000077559), calcium (MESH:D002118), cholecalciferol (MESH:D002762), bisphosphonates (MESH:D004164), 25(OH)D (-), nitrate (MESH:D009566), thyroxine (MESH:D013974), nitric oxide (MESH:D009569), glucose (MESH:D005947), lithium (MESH:D008094), blood glucose (MESH:D001786), caffeine (MESH:D002110), creatinine (MESH:D003404), phosphate (MESH:D010710)
- **Species:** Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027883/full.md

---
Source: https://tomesphere.com/paper/PMC13027883